← All trials
NCT05890963
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 28, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Feb 28, 2025
- First posted
- Jun 6, 2023
- Last posted
- Dec 18, 2023
- Enrollment
- 20
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Columbia UniversityLead sponsor
- Columbia UniversitySponsor investigator
- Henry M. Jackson Foundation for the Advancement of Military MedicineCollaborator
- United States ArmyCollaborator
- Columbia UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.